Nurix Therapeutics (NRIX) Financials

Nurix Therapeutics (NASDAQ: NRIX) continues to look like a cash-rich clinical-stage biotech with meaningful operating losses and no sign yet of commercial profitability. The latest quarter showed higher revenue, but spending remains far above sales, and the company continues to rely on its balance sheet and periodic equity issuance to fund operations.

What stands out most in Q1 2026: revenue improved year over year, but losses widened and cash burn remained heavy. Nurix generated just $6.3 million in revenue, while operating expenses totaled nearly $98.7 million, producing an operating loss of $92.5 million and a net loss of $87.2 million. On the cash flow statement, operating cash flow was negative $71.9 million.

• Revenue increased to $6.25 million in Q1 2026 from $5.31 million in Q1 2025, showing modest top-line growth.
• Nurix still has a substantial liquidity cushion, with $71.2 million in cash and equivalents plus $469.5 million in short-term investments at the end of Q1 2026.
• Total current assets of $554.4 million are far above current liabilities of $92.2 million, suggesting near-term balance sheet flexibility.
• The company continued to earn interest and investment income, which helped offset losses at the pre-tax line.
• Non-cash expenses such as depreciation and amortization continue to support reported losses without directly impacting cash the same way as operating losses do.
• Nurix has consistently maintained a large investment portfolio, which has helped support liquidity despite ongoing cash burn.
• Shares outstanding have risen over time, reflecting repeated equity issuance to fund operations.
• Operating expenses remain extremely high at $98.7 million, driven mainly by $84.1 million in R&D spending.
• Net income remained deeply negative at -$87.2 million in Q1 2026, versus -$56.4 million in Q1 2025.
• Operating cash flow was -$71.9 million in the quarter, showing the business is still burning significant cash.

Trend over the last several years: revenue has been volatile but generally modest, while losses have stayed large and persistent. Quarterly revenue moved from about $10.8 million to $44.1 million at its peak in the periods provided, then dropped back into the single-digit millions in the latest quarter. Meanwhile, R&D has stayed elevated, which is typical for a biotech company advancing a pipeline, but it also means profitability remains distant.

On the balance sheet, Nurix has remained well capitalized, but that cushion has been shrinking over time as cash burn continues. Cash and investments were above $600 million in early 2025 and stand at about $541 million in Q1 2026, so the company still has time to execute. Still, the steady decline in liquidity and repeated share issuance are important risks for retail investors to watch.

Bottom line: NRIX looks financially stable in the near term because of its cash and investment balance, but the core business is still not self-funding. For investors, the key question is whether pipeline progress can eventually justify the heavy R&D spending and offset ongoing dilution and cash burn.